Sarah Ketterer’s Quest Diagnostics DGX Stock Holding History

Sarah Ketterer’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-120,400	Closed	-$20.4M	–	102
2025 Q1	$20.4M	Sell	120,400 -184,081	-60%	-$30.2M	0.43%	48
2024 Q4	$45.9M	Sell	304,481 -37,579	-11%	-$5.84M	1.05%	28
2024 Q3	$53.1M	Sell	342,060 -134,056	-28%	-$20M	1.3%	23
2024 Q2	$65.2M	Sell	476,116 -25,001	-5%	-$3.42M	1.78%	16
2024 Q1	$66.7M	Buy	501,117 +8,410	+2%	+$1.09M	1.75%	15
2023 Q4	$67.9M	Buy	492,707 +3,013	+0.6%	+$396K	1.73%	17
2023 Q3	$59.7M	Buy	489,694 +181,201	+59%	+$24.1M	1.58%	14
2023 Q2	$43.4M	Buy	+308,493	New	+$42.5M	1.14%	24
2021 Q3	–	Sell	-305,502	Closed	-$40.3M	–	83
2021 Q2	$40.3M	Sell	305,502 -14,070	-4%	-$1.84M	0.82%	38
2021 Q1	$41M	Buy	+319,572	New	+$39.4M	0.81%	36

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Sarah Ketterer's DGX Position: Q2 2025 in Review

Sarah Ketterer sold out of Quest Diagnostics (DGX) in Q2 2025, closing a stake of 120,400 shares — an estimated $20.4M sold.

Sarah Ketterer first reported a position in DGX in Q1 2021 and held it in 10 quarters. The position peaked at $67.9M in Q4 2023. 991 funds tracked by Wall St. Rank hold DGX as of Q2 2025.

Sarah Ketterer reported no remaining Quest Diagnostics position as of Q2 2025 after selling out during the quarter.
Sarah Ketterer sold 120,400 Quest Diagnostics shares in Q2 2025, an estimated $20.4M.
Sarah Ketterer first reported a position in Quest Diagnostics in Q1 2021 and held it in 10 quarters.
Sarah Ketterer's Quest Diagnostics position peaked at $67.9M in Q4 2023.
991 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2025.

Based on Causeway Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.